Susac's syndrome - A new ocular finding and disease outcome.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
04 2022
04 2022
Historique:
received:
19
09
2020
accepted:
09
02
2021
revised:
20
01
2021
pubmed:
22
4
2021
medline:
15
4
2022
entrez:
21
4
2021
Statut:
ppublish
Résumé
Susac's syndrome, a rare autoimmune vasculo-occlusive disease, may pose a diagnostic challenge and result in a devastating ocular and systemic outcome. Our study identifies a new retinal finding and evaluates disease outcome. We aimed to assess clinical and imaging findings, systemic manifestations and disease outcome in patients with ocular Susac's syndrome under immunosuppressive/immunomodulation therapies. Retrospective tertiary center study including patients with a diagnosis of Susac's syndrome with >12 months follow up. Medical record review including ocular, neurological and auditory clinical and imaging findings, and treatment modalities. Main outcome measures were clinical manifestations and disease outcome. Seven patients (14 eyes) with a mean age of 34.1 years were included. Mean follow-up was 31.9 months (12.4-72.4). All had bilateral ocular disease. Retinal microaneurysms, a new ocular finding, were demonstrated in 5 patients and persisted at the final visit. In 5 eyes, they further extended during follow-up. All were treated with immunosuppressive drugs and 5/7 additional immunomodulation therapy. At last examination, best corrected visual acuity was >20/40 in all eyes, 1/10 eyes had visual field deterioration, no eye had active ocular disease, all patients achieved neurological stability, and 1 patient had auditory deterioration. Retinal microaneurysms, a new ocular finding in Susac's syndrome, were present in most of our patients, indicating ischemic retinal damage. Immunosuppressive and immunomodulation therapies seem to be highly effective in the control of disease activity.
Sections du résumé
BACKGROUND
Susac's syndrome, a rare autoimmune vasculo-occlusive disease, may pose a diagnostic challenge and result in a devastating ocular and systemic outcome. Our study identifies a new retinal finding and evaluates disease outcome. We aimed to assess clinical and imaging findings, systemic manifestations and disease outcome in patients with ocular Susac's syndrome under immunosuppressive/immunomodulation therapies.
METHODS
Retrospective tertiary center study including patients with a diagnosis of Susac's syndrome with >12 months follow up. Medical record review including ocular, neurological and auditory clinical and imaging findings, and treatment modalities. Main outcome measures were clinical manifestations and disease outcome.
RESULTS
Seven patients (14 eyes) with a mean age of 34.1 years were included. Mean follow-up was 31.9 months (12.4-72.4). All had bilateral ocular disease. Retinal microaneurysms, a new ocular finding, were demonstrated in 5 patients and persisted at the final visit. In 5 eyes, they further extended during follow-up. All were treated with immunosuppressive drugs and 5/7 additional immunomodulation therapy. At last examination, best corrected visual acuity was >20/40 in all eyes, 1/10 eyes had visual field deterioration, no eye had active ocular disease, all patients achieved neurological stability, and 1 patient had auditory deterioration.
CONCLUSION
Retinal microaneurysms, a new ocular finding in Susac's syndrome, were present in most of our patients, indicating ischemic retinal damage. Immunosuppressive and immunomodulation therapies seem to be highly effective in the control of disease activity.
Identifiants
pubmed: 33879856
doi: 10.1038/s41433-021-01464-7
pii: 10.1038/s41433-021-01464-7
pmc: PMC8956676
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
781-788Informations de copyright
© 2021. The Author(s), under exclusive licence to The Royal College of Ophthalmologists.
Références
Susac JO. Susac’s syndrome: the triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology. 1994;44:591–3. https://www.ncbi.nlm.nih.gov/pubmed/8164809
doi: 10.1212/WNL.44.4.591
Egan RA. Diagnostic criteria and treatment algorithm for Susac syndrome. J Neuroophthalmol. 2019;39:60–67. https://www.ncbi.nlm.nih.gov/pubmed/29933288
doi: 10.1097/WNO.0000000000000677
Gross CC, Meyer C, Bhatia U, Yshii L, Kleffner I, Bauer J, et al. CD8+ T cell-mediated endotheliopathy is a targetable mechanism of neuro-inflammation in Susac syndrome. Nat Commun. 2019;10:5779. https://doi.org/10.1038/s41467-019-13593-5
doi: 10.1038/s41467-019-13593-5
pubmed: 31852955
pmcid: 6920411
Jarius S, Kleffner I, Dörr JM, Sastre-Garriga J, Illes Z, Eggenberger E, et al. Clinical, paraclinical and serological findings in Susac syndrome: an international multicenter study. J Neuroinflammation. 2014;11:46. https://www.ncbi.nlm.nih.gov/pubmed/24606999
doi: 10.1186/1742-2094-11-46
Jarius S, Neumayer B, Wandinger KP, Hartmann M, Wildemann B. Anti-endothelial serum antibodies in a patient with Susac’s syndrome. J Neurol Sci. 2009;285:259–61. https://www.ncbi.nlm.nih.gov/pubmed/19643446
doi: 10.1016/j.jns.2009.07.002
Magro CM, Poe JC, Lubow M, Susac JO. Susac syndrome: an organ-specific autoimmune endotheliopathy syndrome associated with anti-endothelial cell antibodies. Am J Clin Pathol. 2011;136:903–12. https://www.ncbi.nlm.nih.gov/pubmed/22095376
doi: 10.1309/AJCPERI7LC4VNFYK
Kleffner I, Dörr J, Ringelstein M, Gross CC, Böckenfeld Y, Schwindt W, et al. Diagnostic criteria for Susac syndrome. J Neurol Neurosurg Psychiatry. 2016;87:1287–95. https://www.ncbi.nlm.nih.gov/pubmed/28103199
doi: 10.1136/jnnp-2016-314295
Bernard JT, Romero R, Agrawal K, Jager R, Rezania K. Optical coherence tomography in Susac’s syndrome. Mult Scler Relat Disord. 2014;3:110–6. https://www.ncbi.nlm.nih.gov/pubmed/25877981
doi: 10.1016/j.msard.2013.05.005
Brandt AU, Oberwahrenbrock T, Costello F, Fielden M, Gertz K, Kleffner I, et al. Retinal lesion evolution in SUSAC syndrome. Retina. 2016;36:366–74. https://www.ncbi.nlm.nih.gov/pubmed/26200513
doi: 10.1097/IAE.0000000000000700
Rennebohm RM, Egan RA, Susac JO. Treatment of Susac’s syndrome. Curr Treat Options Neurol 2008;10:67–74. https://www.ncbi.nlm.nih.gov/pubmed/18325301
doi: 10.1007/s11940-008-0008-y
Ringelstein M, Albrecht P, Kleffner I, Bühn B, Harmel J, Müller A-K, et al. Retinal pathology in Susac syndrome detected by spectral-domain optical coherence tomography. Neurology. 2015;85:610–8. https://www.ncbi.nlm.nih.gov/pubmed/26203089
doi: 10.1212/WNL.0000000000001852
Salvanos P, Moe MC, Utheim TP, Bragadóttir R, Kerty E. Ultra-wide-field fundus imaging in the diagnosis and follow-up of Susac syndrome. Retin Cases Brief Rep. 2018;12:234–9. https://www.ncbi.nlm.nih.gov/pubmed/27828899
doi: 10.1097/ICB.0000000000000470
Saw VP, Canty PA, Green CM, Briggs RJ, Cremer PD, Harrisberg B, et al. Susac syndrome: microangiopathy of the retina, cochlea and brain. Clin Exp Ophthalmol. 2000;28:373–81. https://www.ncbi.nlm.nih.gov/pubmed/11097286
doi: 10.1046/j.1442-9071.2000.00345.x
Spiess K, Martínez JRG. OCT angiography: assessment of retinal ischemia in Susac’s syndrome. Ophthalmic Surg Lasers Imaging Retina. 2017;48:505–8. https://www.ncbi.nlm.nih.gov/pubmed/28613358
doi: 10.3928/23258160-20170601-10
Vishnevskia-Dai V, Chapman J, Sheinfeld R, Sharon T, Huna-Baron R, Manor RS, et al. Susac syndrome: clinical characteristics, clinical classification, and long-term prognosis. Medicine. 2016;95:e5223–e5223. https://www.ncbi.nlm.nih.gov/pubmed/27787385
doi: 10.1097/MD.0000000000005223
Yepez JB, Murati FA, Pettito M, Arevalo JF. Intravitreal triamcinolone in susac syndrome. Retin Cases Brief Rep. 2017;11:236–9. https://www.ncbi.nlm.nih.gov/pubmed/27276498
doi: 10.1097/ICB.0000000000000344
Dörr J, Radbruch H, Bock M, Wuerfel J, Brüggemann A, Wandinger KP, et al. Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome. Nat Rev Neurol. 2009;5:683–8. https://www.ncbi.nlm.nih.gov/pubmed/19953118
doi: 10.1038/nrneurol.2009.176
Dörr J, Krautwald S, Wildemann B, Jarius S, Ringelstein M, Duning T, et al. Characteristics of Susac syndrome: a review of all reported cases. Nat Rev Neurol. 2013;9:307–16. https://www.ncbi.nlm.nih.gov/pubmed/23628737
doi: 10.1038/nrneurol.2013.82
Buelens T, Ossewaarde-van Norel J, de Boer JH, Nubourgh I, Glibert G, Kamgang Semeu P, et al. Evaluation of tumor necrosis factor inhibitor therapy in susac syndrome. Retina. 2019: https://doi.org/10.1097/IAE.0000000000002466. Available at: https://www.ncbi.nlm.nih.gov/pubmed/30707148
Egan RA, Ha Nguyen T, Gass JDM, Rizzo JF 3rd, Tivnan J, Susac JO. Retinal arterial wall plaques in Susac syndrome. Am J Ophthalmol. 2003;135:483–6. https://www.ncbi.nlm.nih.gov/pubmed/12654364
doi: 10.1016/S0002-9394(02)02085-8
Egan RA, Hills WL, Susac JO. Gass plaques and fluorescein leakage in Susac Syndrome. J Neurol Sci. 2010;299:97–100. https://www.ncbi.nlm.nih.gov/pubmed/20880549
doi: 10.1016/j.jns.2010.08.043
Egan RA, Jirawuthiworavong G, Lincoff NS, Chen JJ, Francis CE, Leavitt JA. Retinal arterio-arterial collaterals in Susac syndrome. J Neuroophthalmol. 2018;38:459–61. https://www.ncbi.nlm.nih.gov/pubmed/29341996
doi: 10.1097/WNO.0000000000000627
Heng LZ, Bailey C, Lee R, Dick A, Ross A. A review and update on the ophthalmic implications of Susac syndrome. Surv Ophthalmol. 2019;64:477–85. https://www.ncbi.nlm.nih.gov/pubmed/30703404
doi: 10.1016/j.survophthal.2019.01.007
Martinet N, Fardeau C, Adam R, Bodaghi B, Papo T, Piette J-C, et al. Fluorescein and indocyanine green angiographies in Susac syndrome. Retina 2007;27:1238–42. https://www.ncbi.nlm.nih.gov/pubmed/18046231
doi: 10.1097/IAE.0b013e31809ff824
Mastropasqua R, Toto L, Senatore A, D’Uffizi A, Neri P, Mariotti C, et al. Optical coherence tomography angiography findings in Susac’s syndrome: a case report. Int Ophthalmol. 2018;38:1803–8. https://www.ncbi.nlm.nih.gov/pubmed/28730399
doi: 10.1007/s10792-017-0653-9
Mateen FJ, Zubkov AY, Muralidharan R, Fugate JE, Rodriguez FJ, Winters JL, et al. Susac syndrome: clinical characteristics and treatment in 29 new cases. Eur J Neurol. 2012;19:800–11. https://www.ncbi.nlm.nih.gov/pubmed/22221557
doi: 10.1111/j.1468-1331.2011.03627.x
Rennebohm RM, Asdaghi N, Srivastava S, Gertner E Guidelines for treatment of Susac syndrome - An update. Int. J. Stroke. 2018: 1747493017751737–1747493017751737. Available at: https://www.ncbi.nlm.nih.gov/pubmed/29319463 .
Tomiyasu T, Hirano Y, Suzuki N, Esaki Y, Yasuda Y, Uemura A, et al. Structural and functional analyses of retinal ischemia in eyes with retinal vein occlusion: relationship with macular edema or microaneurysm formation. Ophthalmic Res. 2019;61:218–25. https://www.karger.com/DOI/10.1159/000493489
doi: 10.1159/000493489